By comparison, the IMbrave15017 and Orient327 studies, which investigated the combination of ICIs with anti-VEGF therapies for late-stage HCC, reported mPFS of 6.9 months (HR: 0.59) and 4.6 months (HR: 0.56), respectively. This evidence concerns the gene VEGFA and hepatocellular carcinoma.